β-elemene

Phase 3Small molecule

PPeking Union Medical College Hospital

β-elemene is one of 120 small molecule programs targeting Malignant Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant GliomaActive, not recruiting

Liver CancerActive, not recruiting

GlioblastomaActive, not recruiting

Malignant GliomaPhase 3

Active, not recruiting

Liver CancerPreclinical

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

514 competitors in Glioblastoma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

161 2

Ceenu

AAzurity Pharmaceuticals

Phase 3

22 3

Gleevec

Novartis

Phase 3

2 4

Cymbalta

Alnylam Pharmaceuticals

Phase 3

1 5

Scemblix

Novartis

Phase 3

1 6

Lexapro

AbbVie

Phase 3

1 7

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 8

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

4 9

Feraheme

AAzurity Pharmaceuticals

Phase 3

4 10

Droxia

TTheravia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Glioblastoma

NCT05842746

Clinical

Trials by Indication[1]

Glioblastoma2 trials

Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04674527·30 enrolled

Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05842746·74 enrolled

Advanced1 trial

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Unknown status·—·Phase 2·NCT03123484·80 enrolled

Malignant Glioma1 trial

A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas

Unknown status·SSun Yat-sen University·Phase 3·NCT02629757·100 enrolled

Liver Cancer1 trial

Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer

Unknown status·BBeiJing Yijiayi Medicine Techonoloy Co., Ltd.·N/A·NCT03166553·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for β-elemene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — β-elemene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for β-elemene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking Union Medical College Hospital

β-elemene

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Glioblastoma2 trials

Advanced1 trial

Malignant Glioma1 trial

Liver Cancer1 trial

References

Drug Info

Quick Facts

Related News